Pharmafile Logo

First Edition Translations Ltd

Founded in 1981, First Edition Translations Ltd is one of the UK’s oldest established translation agencies and a founder member of the Institute of Translation and Interpreting. Our team of professional medical translators are fluent in over 30 languages, ensuring your documents and materials are accurately translated.

First Edition offers diverse medical translation services that cover a broad range of materials, including:
Regulatory and legal documents
SPCs, PILs, labelling, treatment manuals
Clinical trials, assessments
Research studies, papers and abstracts
Information, manufacturing and marketing materials, IFUs
Specialist published materials, including catalogues, industry magazines and newsletters
Websites, apps and software

We value accuracy, reliability and outstanding quality, making us a trusted partner for all your medical and pharmaceutical translations. Adhering to the ISO 17100 standard, we can provide certification for our work upon request. If you’d like further advice, our friendly and multilingual project management team is always happy to help.

This is a FREE LISTING on PMHUB

Below are full profiles from other companies in related areas

Atlas Translations Ltd

With Atlas Translations Ltd you get a service that is both personal and professional. This means that your message will be understood in the language and context you need it…

View Profile

Streaming Well

Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual stories and interactive experiences that connect with people.

View Profile

Company Details

6 Wellington Court, Wellington Street, Cambridge, CB1 1HZ, United Kingdom
+44 (0)1223 356 733

 Latest Content from PMHub 

Moving Beyond the Pill: Unlocking Value Through Engaged, Empowered, and Educated Patients

True "beyond-the-pill" strategy requires shifting from a prescriptive model to a supportive one—using personalized digital tools and authentic patient voices to drive adherence, improve outcomes, and prove value.

The Heart of the Matter: Medscape Education’s Cardiology Footprint at ESC 2026

For more than 30 years, Medscape Education has built independent, accredited cardiovascular education designed around one goal: improved patient outcomes. This year at the European Society of Cardiology Congress (ESC...

A seat at the table: what the EU HTA reforms really ask of patient involvement

The EU HTA reforms give patients a formal role in assessing new medicines, but meaningful involvement requires more than simply offering them a seat at the table.

What do patient stories actually teach us?

Press Releases | July 21, 2026 | Mednet

How do we translate individual experiences into support that helps others and create support that feels personal but remains relevant to many?

Infographic: Are data blind spots putting your launch at risk?

Commercial pharma launches depend on confident, evidence-led decisions. Yet many launch teams are still working with fragmented data spread across multiple systems, making it difficult to understand market readiness, prioritize...

Key takeaways from ASCO® 2026

Following ASCO® 2026, Inizio's experts have shared their perspectives across three thought leadership articles, each exploring a different aspect of what this year's congress revealed for pharmaceutical organisations. Together, they...

More Than Pink Walls: What Women-Centric Care Actually Requires

The phrase "patient-centered care" is tossed around freely in healthcare corporate boardrooms. Yet, for more than half the population, that promise routinely fractures. In the latest episode of the Hear...

Why faster trials make participant understanding more important than ever

As clinical trials accelerate, clear, accessible consent is essential to help participants understand, engage with and remain in a study.

Real Chemistry Launches Real Chemistry ANATOMI, an AI Ecosystem Purpose-Built for Healthcare Commercialization

Press Releases | July 14, 2026 | Real Chemistry

The unique combination of technology marks 25 years of industry innovation and expertise, and signals company’s next phase of business growth and client value

Older trial participants reject bad design, not technology

Older trial participants aren’t rejecting digital technology — they’re rejecting poorly designed, inaccessible experiences that make participation harder.